Results 21 to 30 of about 1,772,527 (156)

Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings

open access: yesActa Medica Bulgarica, 2021
Introduction: Azacitidine is one of the hypomethylating agents available for the treatment of elderly patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
Nikolova D., Yordanov A., Radinov A.
doaj   +1 more source

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis

open access: yesHaematologica, 2010
Hypomethylating agents have recently been shown to improve the outcome of patients with myelodysplastic syndrome. A meta-analysis and systematic review was carried out of randomized controlled trials comparing treatment with hypomethylating agents to ...
Ronit Gurion   +6 more
doaj   +1 more source

Maintenance Therapy in AML

open access: yesFrontiers in Oncology, 2021
Recent advances in therapeutics coupled with steady improvements in supportive care for patients with acute myeloid leukemia (AML) have led to improved outcomes.
Patrick K. Reville, Tapan M. Kadia
doaj   +1 more source

Significant independent predictors of OS and LFS in patients treated with hypomethylating agents (n = 377).

open access: yes, 2016
Significant independent predictors of OS and LFS in patients treated with hypomethylating agents (n = 377).
Youngil Koh (3196416)   +21 more
core   +1 more source

Leveraging Hypomethylating Agents for Better MDS Therapy

open access: yes, 2018
Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a ...
Watts, Justin M   +5 more
core   +1 more source

Minimal Residual Disease Evaluation in Acute Myeloid Leukemia patients treated with Venetoclax and Hypomethylating Agents [PDF]

open access: yes, 2021
Acute myeloid leukemia (AML) is a genetically heterogeneous malignant clonal disorder of the hematopoietic system. Treatment of older patients with AML is quite challenging, an older age is independently associated with an inferior outcome ...
Abbenante, Mariachiara <1984>
core   +1 more source

Hypomethylating agent versus venetoclax combination: an electronic health records-based target trial emulation among Asian elderly patients with newly diagnosed acute myeloid leukaemia in Hong Kong

open access: yesTherapeutic Advances in Hematology
Background: The pivotal trial on venetoclax and hypomethylating agents in unfit elderly acute myeloid leukaemia (AML) has got FDA approval. However, Asian patients were under-represented and showed no survival advantage.
Qiwen Fang   +10 more
doaj   +1 more source

Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes

open access: yesHaematologica
Not available.
Mahmood Aldapt   +21 more
doaj   +1 more source

GBS‐MeDIP: A method for the simultaneous identification of genetic and epigenetic variants in tumors

open access: yesFEBS Open Bio, EarlyView.
GBS‐MeDIP combines DNA sequencing with enrichment of methylated DNA to profile genetic and epigenetic variation in the same reduced genomic fraction. Applied to gastric cancer and parathyroid tumors, it identifies sequence variants, copy number changes, and differentially methylated regions together, helping distinguish true epigenetic changes from ...
Fábio Pértille   +6 more
wiley   +1 more source

A Metabolic‐Epigenetic Axis of AARS1/IGF2BP3‐K280 Lactylation Sustains Endometrial Cancer Stemness and Recurrence

open access: yesAdvanced Science, EarlyView.
Lactate‐driven endometrial cancer relapse is mediated by enzymatic protein modification. Elevated lactate levels activate AARS1, which catalyzes K280 lactylation of IGF2BP3, therefore stabilizing HMGA2 mRNA and promoting tumor stemness and recurrence.
Peng Jiang   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy